Posted on

MARK1 – A Decision Support System for the Early Detection of Malignant Melanoma

MARK1 is one of the 31 proposals that will be funded under the “Bilateral S & T Cooperation between Greece – Israel 2013-2015″ call, of the National Action Range” Bilateral, Multilateral and Regional S & T Partnerships”. The project is partially funded by the National Strategic Reference Framework (NSRF) (Grant Agreement No ISR_3233) and runs in the period June 2014 – September 2015. Within the context of MARK1, UBITECH collaborates with the MEDical Image and Signal Processing laboratory (MEDISP) of the Technological Educational Institute of Athens, the Department of Medical Physics of the University of Patras, as well as Emerald Medical Applications, an Israeli software development SME with rich experience in Image Processing technology applied to the medical field of Dermatology.

The vision of the MARK1 project is to address the need for early and accurate detection of malignant melanoma, through the intelligent and automatic scanning of the entire human body, facilitating the automatic focus on areas suspicious for skin cancer, while coupling the automation process with human experts supervision and guidance, as well as to enable the follow up and monitoring for further analysis or treatment whenever and wherever necessary, through a screening solution that will be easily accessible to the general public and location-independent. The proposed solution shall provide painless, effortless and efficient self-screening of skin lesions, for early, accurate detection of melanoma, independent of the patient’s location, safeguard sensitive patient data and maintain patient-doctor confidentiality, as well as ensure accurate diagnosis delivered by the specialist (physician), independent of the physician’s and patient’s physical locations.

UBITECH participates in the design, technical specification and implementation of the Secure Skin Cancer Image Database Connectors to existing databases of melanoma (skin cancer) images of patients, respecting their anonymity, which are either hosted in clinical premises or are available online, free of charge for research purposes. In addition, UBITECH participates in the design, technical specification and implementation of the Suspicious Mole Still Image Capture Module, which utilises the camera of a smartphone in order to capture high definition still images of the highlighted suspicious moles, and of the Suspicious Mole Still Image Synchronisation Module, which is responsible for uploading the acquired images to upload to platform server, and synchronizing them with the patient’s health record. Last but not least, UBITECH will undertake the design, technical specification and implementation of the front ends through which the healthcare professionals will be able to interact with the MARK1 platform, through standard handheld devices. Within the context of the project, different front ends will be developed and delivered to healthcare professionals / dermatologists and patients, based on the discrete needs on information access.